Jci_page_head_homepage_01 Jci_page_head_homepage_02
Biva M. Desai, Jennifer Oliver-Krasinski, Diva D. De Leon, Cyrus Farzad, Nankang Hong, Steven D. Leach, Doris A. Stoffers
Published in Volume 117, Issue 4
J Clin Invest. 2007; 117(4):971–977 doi:10.1172/JCI29988
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 6
No evidence of acinar-to-islet transdifferentiation after cerulein-induced pancreatitis.

ElastaseCreERT2Tg/+Rosa26r+/– mice were treated with TAM for 3 weeks by subcutaneous continuous delivery pellet and subjected to a 2-day course of serial cerulein injections as described in Methods. (AC) Severe exocrine inflammation but intact islets were evident 1 day after the initiation of treatment (A and B), with histologic recovery by 7 days (C). Cerulein-treated mice were randomized to receive daily injections of vehicle or Ex-4 (1 nmol/kg body wt i.p.) on day 3, the time of maximal Notch activation. (DF) Tissues were harvested on day 7, and β-galactosidase activity (blue stain) and insulin immunoreactivity (red stain) were visualized. (D) Pancreas from a control mouse that received only PBS vehicle. (E and F) Pancreata from cerulein-treated mice that received vehicle (E) or Ex-4 (F). Original magnification, ×200.